divergent protein kinase domain 1BGenealiases: C9orf136 · FAM69B · pp6977
Q-omics provides the consensus-scored DIPK1B profile across patient tissues and cancer cell-line models. DIPK1B expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, DIPK1B is differentially expressed in 11, with the highest sampling consensus in LUSC. Additionally, DIPK1B RNA expression shows 19,600 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight COAD, LUSC, and LSCC as cancer lineages where DIPK1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DIPK1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DIPK1B survival associations across molecular data types. DIPK1B RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DIPK1B RNA expression–survival associations across cancer types. High DIPK1B expression shows unfavorable associations in COAD, ACC, MESO and SKCM, but favorable associations in UVM and PAAD. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for DIPK1B RNA expression.
This table summarizes DIPK1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for DIPK1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DIPK1B shows lower tumor expression in LUSC, KIRC, KIRP, LUAD and BRCA and higher tumor expression in LIHC. The LUSC box plot shows higher DIPK1B RNA expression in normal versus tumor tissue (log2 FC = −1.175, t-test p < 0.001).
This table shows molecular features associated with DIPK1B in patient tissues and cancer cell lines. In patient samples, DIPK1B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, DIPK1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
